Zotarolimus eluting stent verses GENOUS stent in patients with ST-elevation myocardial infarction undergoing primary PCI

Trial Profile

Zotarolimus eluting stent verses GENOUS stent in patients with ST-elevation myocardial infarction undergoing primary PCI

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Anti-CD34 monoclonal antibody (Primary) ; Zotarolimus (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Dec 2016 New trial record
    • 01 Nov 2016 Primary endpoint (Target lesion failure at 1 month) has been met according to the results published in the Journal of the American College of Cardiology.
    • 01 Nov 2016 Results published in the Journal of the American College of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top